Navigation Links
Combating mood disorders
Date:9/30/2011

Psychiatric ailments such as depression, obsessive-compulsive disorder or anxiety states are often associated with disturbances in the metabolism of the neurotransmitter serotonin. Neurotransmitters are compounds that are released from the synapses at nerve cell endings and activate the firing of neighboring neurons. Thus, as their name suggests, they mediate the transmission of nerve impulses. The serotonin transporter (SERT) is responsible for reuptake of the transmitter into neurons, terminating its action. SERT is a major target for drugs that are used to treat many mood disorders, and the search for new SERT inhibitors is of continuing therapeutic relevance. A research team led by Professor Klaus Wanner of the Department of Pharmacy in the Center for Pharmaceutical Research at Ludwig-Maximilians Univeristt Mnchen (LMU) has now developed a novel binding assay, based on the use of mass spectrometry (MS), which promises to simplify the search for potential SERT inhibitors very significantly. The major advantage of the technique is that, unlike conventional binding assays, it avoids the need to use radiolabeled substances. A paper that describes the new assay will appear in the journal ChemMedChem on 4. October. The article has been rated as a "very important paper" and is featured on the cover of the upcoming issue of the journal.

To be effective, most drugs must bind selectively to defined molecular targets in the body. The target may be an enzyme found in certain cells or a protein on the plasma membrane of a specific cell type. Drug candidates must therefore be assessed for their affinity for the target by means of binding assays. These assays often involve the use of a chemical that is already known to recognize and bind selectively to the target as. The ability of a test substance to find and interact with the target is then measured in terms of how well it competes with this "marker" ligand. The greater its ability to displace the marker from the binding site, the higher is its own affinity for the target, and the more likely it is to be clinically effective. In the MS-based binding assay developed by Wanner's group, quantification of the marker is carried out using mass spectrometry. In contrast to conventional techniques, which employ radiolabeled ligands, MS binding assays do not require the use of markers containing radioactive isotopes. This means that the marker can be assayed in its unaltered, native state. "This label-free technique provides all the advantages offered by classical binding studies, while avoiding the need to work with radioactive compounds," explains Wanner. His team has now validated the MS-based binding assay for use in the search for new inhibitors of SERT function. "Because SERT regulates the concentration of serotonin in the synaptic cleft, the protein serves as the major target for the treatment of depression, obsessive-compulsive disorders and anxiety states," says Wanner. Using the well-known antidepressant (S)-fluoxetine as a native marker, his group has now shown that the results of the MS-based assay are in very good agreement with those obtained using radiolabeled ligands. Indeed, the team now routinely uses the MS method to screen for novel, pharmacologically active SERT inhibitors. In addition, Wanner has plans to adapt the approach for use with other target molecules of clinical interest. (gd)


'/>"/>

Contact: Dr. Kathrin Bilgeri
kathrin.bilgeri@lmu.de
49-892-180-6938
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. Combating the C. diff terrorists on the loose in hospitals
2. Combating Myths About Seasonal Allergies
3. Combating cancers double whammy
4. Holistic Management and Allan Savory Win the 2010 Buckminster Fuller Award for Turning Deserts into Thriving Grasslands and Combating Climate Change.
5. YouTube videos can inaccurately depict Parkinson’s disease and other movement disorders
6. Movement Disorders on YouTube Not What They Seem, Experts Warn
7. People born after World War II are more likely to binge drink and develop alcohol disorders
8. Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes
9. The size and burden of mental disorders in Europe
10. Study linking gut microbe type with diet has implications for fighting GI disorders
11. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: